WALTHAM, Mass., May 24, 2017 -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that management will participate in the 14th Annual Craig-Hallum Institutional Investor Conference, to be held in Minneapolis on Wednesday, May 31, 2017.
About Repligen Corporation
Repligen Corporation (NASDAQ:RGEN) is a bioprocessing company focused on the development, manufacture and commercialization of highly innovative products used to improve the biological drug manufacturing process. Our portfolio includes Protein products (Protein A affinity ligands, cell culture growth factors), Chromatography products (OPUS® pre-packed columns, chromatography resins, ELISA kits) and Filtration products (XCell™ ATF Systems, TangenX™ Sius™ TFF cassettes). Our bioprocessing products are sold to major life sciences companies, biopharmaceutical development companies and contract manufacturing organizations worldwide. We are the leading manufacturer of Protein A ligands, a critical component of Protein A resins that are the industry standard for downstream separation and purification of monoclonal antibody-based therapeutics. Our growth factors are a key component of cell culture media used in upstream processes to accelerate cell growth and productivity in a bioreactor. Our innovative line of OPUS® chromatography columns, used in downstream processes for bench-scale through clinical-scale purification needs, are delivered pre-packed with our customers’ choice of resin and bed height. Our XCell™ ATF Systems, available in stainless steel and single-use configurations, continuously eliminate waste from a bioreactor to concentrate cells in upstream processes. TangenX Sius™ TFF single-use cassettes and hardware are used for biologic drug concentration in downstream formulation processes. Repligen’s corporate headquarters are in Waltham, MA (USA) and our manufacturing facilities are located in Waltham, MA, Shrewsbury, MA, Lund, Sweden and Weingarten, Germany.
This press release may contain forward-looking statements within the meaning of the federal securities laws. Investors are cautioned that statements in this press release which are not strictly historical statements including, without limitation, statements identified by words like “believe,” “expect,” “may,” “will,” “should,” “seek,” or “could” and similar expressions, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including risks discussed from time to time in our filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update any forward-looking statements, except as required by law.
Contact: Sondra Newman [email protected]


Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries”
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 



